Summary
Wang et al. conducted a functional genetic screen in FGFR-mutant urothelial carcinoma cell lines to identify molecular mechanisms of resistance to FGFR inhibitor therapy. The work implicated the PI3K signalling pathway as a principal determinant of therapeutic resistance, as suggested by the title and publication venue. These findings may inform combination therapeutic strategies targeting both FGFR and PI3K pathways in resistant disease.
UK applicability
This is fundamental cancer cell biology research with potential relevance to UK oncology drug development and precision medicine strategies for urothelial cancer. However, the findings are cell-line derived and would require clinical validation before direct translation to NHS treatment protocols.
Key measures
Gene set enrichment analysis; pathway activation status; cell line sensitivity to FGFR inhibitors; genetic screen hits conferring resistance phenotype
Outcomes reported
The study identified phosphoinositide 3-kinase (PI3K) pathway activation as a key determinant of resistance to fibroblast growth factor receptor (FGFR) inhibitors in FGFR-mutant urothelial cancer cells. The research employed functional genetic screening to elucidate resistance mechanisms in cell culture models.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.